UBS cuts Axsome Therapeutics target price to $239 from $256
AXSM•UBS cut its target price for Axsome Therapeutics to $239 from $256.
Related News
XPLR Infrastructure management commentary: Normalized wind resource drives Q3 2026 adjusted EBITDA gains at existing projects
XIFR•
West Virginia selects Tyler Technologies’ enterprise ERP for statewide modernization
TYL•
Deals of the day: mergers and acquisitions
CVI•
Gold edges higher on softer oil prices; US midterms in focus
GLD•
Onterris says proposed EPA methane rule could expand emissions monitoring market
ONT•